Intellia Therapeutics (NTLA) Operating Leases (2019 - 2025)
Historic Operating Leases for Intellia Therapeutics (NTLA) over the last 7 years, with Q3 2025 value amounting to $70.6 million.
- Intellia Therapeutics' Operating Leases fell 1438.27% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.6 million, marking a year-over-year decrease of 1438.27%. This contributed to the annual value of $190.0 million for FY2024, which is 9633.89% up from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' Operating Leases is $70.6 million, which was down 1438.27% from $75.6 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Operating Leases registered a high of $190.0 million during Q4 2024, and its lowest value of $60.0 million during Q2 2022.
- In the last 5 years, Intellia Therapeutics' Operating Leases had a median value of $82.4 million in 2024 and averaged $88.0 million.
- Per our database at Business Quant, Intellia Therapeutics' Operating Leases surged by 32045.62% in 2021 and then crashed by 1858.23% in 2024.
- Quarter analysis of 5 years shows Intellia Therapeutics' Operating Leases stood at $64.9 million in 2021, then surged by 75.65% to $114.0 million in 2022, then fell by 15.15% to $96.7 million in 2023, then soared by 96.34% to $190.0 million in 2024, then crashed by 62.84% to $70.6 million in 2025.
- Its Operating Leases stands at $70.6 million for Q3 2025, versus $75.6 million for Q2 2025 and $80.5 million for Q1 2025.